查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2004926

强迫症治疗市场：2026-2032年全球市场预测（依药物类别、通路、药物类型、给药途径、最终用户及患者年龄层划分）

Obsessive-Compulsive Disorder Drugs Market by Drug Class, Distribution Channel, Drug Type, Route Of Administration, End User, Patient Age Group - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年强迫症 (OCD) 治疗市场价值 10.5 亿美元，预计到 2026 年将成长至 11.3 亿美元，复合年增长率为 8.91%，到 2032 年将达到 19.1 亿美元。

主要市场统计数据
基准年 2025 10.5亿美元
预计年份：2026年 11.3亿美元
预测年份 2032 19.1亿美元
复合年增长率 (%) 8.91%

针对强迫症药物治疗的简明临床和商业性指南，将治疗的细微差别与策略市场需求相结合。

目前，强迫症（OCD）的药物治疗现况亟需为临床照护、产品开发和市场进入等领域的相关人员提供清晰简洁的指南。本执行摘要首先重点介绍治疗背景，强调强迫症临床表现的复杂性、患者症状的多样性以及药物治疗与认知行为疗法相结合的关键作用。透过强调实证治疗路径和现有药物类别的多样性，本概要为深入分析市场动态、监管影响和供应链考量奠定了基础。

对科学、监管和商业性因素的融合将重塑强迫症药物疗法的开发路径和市场进入策略进行详细说明。

强迫症（OCD）的治疗体係正经历着一场变革，其驱动力来自不断涌现的临床证据、监管政策的调整以及药物研发和递送技术的进步。精准精神病学的最新进展以及对OCD亚型更精细的表型分析，不仅明确了靶点识别，也重新激发了人们对现有抗忧郁症和新型作用机制的兴趣。同时，监管机构正在针对存在高度未满足需求的适应症，明确适应性试验设计和加速审批流程，从而改变研发进度和投资决策。

对 2025 年美国关税措施将如何重塑强迫症药物整个价值链的供应链、采购决策和价格谈判进行全面分析。

美国于2025年实施的关税措施的累积影响正逐渐显现，并波及强迫症（OCD）药物价值链的多个环节，迫使相关人员重新评估供应韧性、成本结构和筹资策略。关税带来的投入成本压力尤其影响活性药物成分和某些特殊辅料，迫使製造商评估替代供应商和生产地点，以在确保产品品质的同时维持获利能力。这些调整与更广泛的行业趋势同步进行，例如双重采购和加强库存缓衝以降低未来贸易政策波动的风险。

根据药物类别、通路、剂型和患者人口统计特征进行策略性细分，以满足差异化的商业性和临床需求。

从精细的市场区隔观点来看，强迫症（OCD）药物治疗领域存在着影响需求、盛行率和竞争压力的差异化商业性动态。从药物类别来看，主要的抗忧郁症类别，例如单胺氧化酵素抑制剂（MAOIs）、5-羟血清素-正肾上腺素再回收抑制剂（SNRIs）、选择性血清素再回收抑制剂（SSRIs）和三环抗忧郁药物，各自展现出不同的疗效和耐受性特征。其中，MAOIs的代表药物包括苯乙肼和反苯环丙胺；SNRIs的代表药物包括Desvenlafaxine、Duloxetine和文拉法辛；SSRIs的代表药物包括西酞普兰、Fluoxetine、氟伏沙明、帕罗西汀和舍曲林；TCAs的代表药物包括阿米咪林、氯米米姆林丙嗪。这些细微的治疗差异会影响处方模式、药物变更倾向和长期用药依从性。

提供切实可行的区域洞察，解释美洲、欧洲、中东和非洲以及亚太地区的市场动态如何需要个人化的商业化和进入策略。

区域特征对强迫症（OCD）药物治疗的研发、报销和实施有显着影响，因此需要製定针对特定区域的策略。在美洲，准入框架、支付方的多样性以及蓬勃发展的民营市场，共同决定了市场准入策略和循证医学证据生成（以支持处方集纳入和报销）的优先顺序。该地区强调以结果为导向的合约和真实世界数据，以在不同的医疗服务模式下展现药物价值。

对企业趋势和竞争定位进行深入分析，重点在于塑造强迫症治疗组合的创新、生命週期管理和伙伴关係策略。

强迫症 (OCD) 治疗领域的竞争格局和企业发展趋势反映出，创新投资、生命週期管理和伙伴关係关係正在融合，以解决产品可及性和差异化问题。各公司正增加对后期临床计画的投入，旨在提高疗效和耐受性，使其优于现有标准疗法；同时，他们也在透过改进配方、开发缓释製剂和联合治疗等方式优化产品组合。随着各公司寻求非药物辅助疗法以改善整体疗效，与学术机构和数位医疗供应商的合作研究也日益普遍。

为高阶主管提供实际有效的建议，以加强强迫症治疗领域的供应韧性、证据产生和价值主导的商业化。

致力于巩固自身在强迫症治疗领域地位的产业领导者应优先采取一系列切实可行且影响深远的措施，以增强自身韧性并实现商业性差异化。首先，他们应从试验设计的早期阶段就将卫生经济学和结果研究纳入考量，使临床开发选择与支付方的证据要求保持一致，并缩短获得保险覆盖的路径。同时，他们应透过区域多元化和策略性生产合约来强化供应链，以降低贸易政策波动带来的风险，并确保供应的连续性。

采用透明、多方面的研究途径，结合关键相关人员的访谈和系统性的二手证据，提供可靠、可重复和具有策略意义的见解。

本次高阶主管分析的基础研究结合了第一手资料和第二手资料，以确保获得全面而深入的见解。第一手资料包括对临床医生、付款者、采购负责人和生产专家进行结构化检验，以了解医疗机构的实际情况、处方行为和取得途径的限制。第二手资料包括对同行评审的临床文献、监管指导文件、临床试验註册资讯和公开的安全报告进行系统性回顾，以检验治疗趋势和证据缺口。

执行总结强调，整合临床差异化、供应弹性和以患者为中心的策略对于在强迫症治疗中取得永续的成果至关重要。

总之，现代强迫症（OCD）治疗领域面临临床、监管和商业方面的双重挑战与机会。临床认识的进步和辅助性数位化干预措施的出现，正为改善患者预后铺平道路；与此同时，贸易政策的转变和学名药竞争的加剧，正在重塑成本和供应动态。因此，决策者必须整合实证实践、供应链韧性和以病人为中心的支援服务，制定符合当地市场实际情况和支付方期望的连贯策略。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：强迫症治疗市场：依药物类别划分

  • MAOI
    • 芬纳嗪
    • 反式环丙胺
  • SNRI
    • Desvenlafaxine
    • Duloxetine
    • 文拉法辛
  • SSRI
    • 西洛普鲁姆
    • Fluoxetine
    • 氟伏沙明
    • 帕罗西汀
    • 舍曲林
  • TCA
    • 阿米替林
    • 氯米帕明
    • 丙咪嗪

第九章 强迫症治疗市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十章：强迫症治疗药物市场－依药物类型划分

  • 品牌药
  • 非专利的

第十一章 强迫症治疗市场：依给药途径划分

  • 口服
  • 肠外

第十二章 强迫症治疗市场：依最终使用者划分

  • 诊所
  • 医院
  • 普通家庭

第十三章：依患者年龄层分類的强迫症治疗药物市场

  • 成人版
  • 儿童

第十四章 强迫症治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 强迫症治疗市场：依群体划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 强迫症治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国强迫症治疗市场

第十八章：中国强迫症治疗药物市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc
  • Alembic Pharmaceuticals Ltd
  • Amneal Pharmaceuticals Inc
  • Apotex Inc
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Biogen Inc
  • Dr Reddy's Laboratories Ltd
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • H Lundbeck A/S
  • Johnson & Johnson
  • Lupin Pharmaceuticals Inc
  • Mallinckrodt plc
  • Merck & Co Inc
  • Novartis AG
  • Omeros Corporation
  • Otsuka Pharmaceutical Co Ltd
  • Pfizer Inc
  • Sanofi
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd
  • Torrent Pharmaceuticals Ltd
  • Viatris Inc
  • Zydus Pharmaceuticals Inc
Product Code: MRR-742BD51822E2

The Obsessive-Compulsive Disorder Drugs Market was valued at USD 1.05 billion in 2025 and is projected to grow to USD 1.13 billion in 2026, with a CAGR of 8.91%, reaching USD 1.91 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.05 billion
Estimated Year [2026] USD 1.13 billion
Forecast Year [2032] USD 1.91 billion
CAGR (%) 8.91%

Concise clinical and commercial orientation to obsessive-compulsive disorder pharmacotherapy that aligns therapeutic nuance with strategic market imperatives

The landscape of pharmacological interventions for obsessive-compulsive disorder demands a clear, concise orientation for stakeholders operating at the intersection of clinical care, product development, and market access. This executive summary opens with a focused introduction to the therapeutic context, highlighting the enduring clinical complexity of OCD, the heterogeneity of patient presentations, and the critical role that pharmacotherapy plays alongside cognitive and behavioral approaches. By emphasizing evidence-based treatment pathways and the diversity of available drug classes, the introduction sets the stage for deeper analysis of market dynamics, regulatory influences, and supply chain considerations.

Transitioning from clinical framing to commercial implications, the introduction underscores the need for integrated strategic thinking that accounts for variations in drug classes, distribution channels, and patient demographics. It clarifies that the subsequent sections synthesize current industry trends, policy shifts, and segmentation intelligence to inform senior-level decisions. This contextual foundation ensures readers appreciate how clinical realities map onto commercial levers, enabling data-driven choices about portfolio prioritization, patient access strategies, and partnership opportunities.

Detailed account of converging scientific, regulatory, and commercial forces reshaping development pathways and market access strategies for OCD pharmacotherapies

The therapeutic ecosystem for obsessive-compulsive disorder is undergoing transformative shifts driven by evolving clinical evidence, regulatory recalibrations, and technological advances in drug development and delivery. Recent progress in precision psychiatry and more refined phenotyping of OCD subtypes has sharpened target identification and reinvigorated interest in both established antidepressant classes and novel mechanisms of action. Concurrently, regulators are clarifying pathways for adaptive trial designs and expedited review for high-unmet-need indications, which is altering development timelines and investment calculus.

On the commercial front, digital therapeutics and telehealth integration are reshaping patient journey touchpoints and altering prescribing behavior, increasing the importance of real-world evidence and post-market pharmacovigilance. Supply chain optimization, strategic manufacturing partnerships, and an intensifying focus on affordability and payer value frameworks represent additional levers redefining market entry and scale. Collectively, these forces are prompting companies to re-evaluate R&D portfolios, pursue differentiated formulations and delivery routes, and adopt more collaborative commercialization models that align clinical benefit with payers' and providers' evolving expectations.

Comprehensive analysis of how the 2025 United States tariff measures are reshaping supply chains, sourcing decisions, and pricing negotiations across the OCD drug value chain

The cumulative impact of the United States tariffs introduced in 2025 is manifesting across multiple nodes of the obsessive-compulsive disorder drug value chain, forcing stakeholders to reassess supply resilience, cost structures, and sourcing strategies. Tariff-induced input cost pressures have particularly affected active pharmaceutical ingredients and certain specialized excipients, prompting manufacturers to evaluate alternative suppliers and production geographies to preserve margins while maintaining product quality. These adjustments have occurred alongside a broader industry trend toward dual sourcing and enhanced inventory buffering to mitigate future trade policy volatility.

Payers, procurement teams, and hospital formularies are responding by intensifying price negotiations and seeking contracting mechanisms that de-risk exposure to tariff-driven cost variability. Regulators and trade bodies have engaged in targeted dialogue to ensure continuity of critical medicines, and some firms have accelerated onshoring and regional manufacturing investments to circumvent duties and shorten lead times. The tariffs have also elevated the importance of transparent cost modeling and scenario planning, encouraging companies to incorporate trade policy risk into supply chain decisions and to explore strategic alliances that can absorb or offset tariff impacts while preserving patient access.

Strategic segmentation synthesis that maps drug classes, channels, formulations, and patient cohorts to differentiated commercial and clinical imperatives

A nuanced segmentation lens reveals the differentiated commercial dynamics that govern OCD pharmacotherapy demand, uptake, and competitive pressures. When examining drug class, major antidepressant categories including monoamine oxidase inhibitors, serotonin-norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors, and tricyclic antidepressants each present distinct efficacy and tolerability profiles, with MAOIs further represented by phenelzine and tranylcypromine, SNRIs by desvenlafaxine, duloxetine, and venlafaxine, SSRIs by citalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline, and TCAs by amitriptyline, clomipramine, and imipramine; these therapeutic nuances influence prescribing patterns, switching behavior, and long-term adherence.

Distribution channel dynamics encompass hospital pharmacies, online pharmacies, and retail pharmacies, each serving different patient access needs and reimbursement pathways and shaping how products are merchandised and supported. Drug type segmentation across brand and generic markets drives pricing strategies, lifecycle management approaches, and commercialization investments. Route of administration-oral versus parenteral-affects formulation priorities, adherence support requirements, and clinical settings for administration. End-user distinctions among clinics, hospitals, and households reflect divergence in procurement cycles, care delivery models, and patient education imperatives. Finally, patient age group segmentation into adult and pediatric cohorts requires distinct safety considerations, dosing paradigms, and regulatory dossiers, making a tailored approach essential for clinical adoption and market penetration.

Actionable regional intelligence explaining how Americas, Europe Middle East & Africa, and Asia-Pacific market dynamics demand tailored commercialization and access strategies

Regional nuances materially affect how OCD pharmacotherapies are developed, reimbursed, and delivered, demanding geographically customized strategies. In the Americas, access frameworks, payer heterogeneity, and a robust private market shape commercialization tactics and prioritization of evidence generation that supports formulary inclusion and reimbursement. This region emphasizes outcomes-oriented contracting and real-world evidence to demonstrate value within diverse healthcare delivery models.

Europe, the Middle East & Africa present a mosaic of regulatory approaches and reimbursement environments, with pronounced differences between centralized regulatory pathways, national health technology assessment requirements, and emerging market constraints; companies must balance harmonized clinical data packages with localized health economic models. The Asia-Pacific region displays rapid adoption of digital health modalities and an expanding role of domestically manufactured generics and biosimilars, necessitating strategies that account for local manufacturing partnerships, variable payer coverage, and cultural dimensions of mental health care. Across all regions, evolving patient advocacy, telemedicine uptake, and regional manufacturing considerations inform differentiated market entry and scaling choices.

Insightful corporate behavior and competitive positioning analysis highlighting innovation, lifecycle management, and partnership strategies shaping OCD therapeutic portfolios

Competitive and corporate behavior within the obsessive-compulsive disorder drug space reflects a blend of innovation investment, lifecycle management, and partnerships to address access and differentiation. Organizations are increasing investment in late-stage clinical programs that seek improved efficacy or tolerability versus existing standards, while simultaneously optimizing portfolios through formulation improvements and extended-release or combination approaches. Research collaborations with academic centers and digital health vendors are becoming more common as companies pursue complementary nonpharmacologic solutions to enhance overall outcomes.

At the same time, generic entrants and established off-patent molecules exert pressure on pricing and reimbursement, compelling originators to emphasize brand value via outcomes data and support services. Strategic licensing, co-promotion, and regional manufacturing agreements are being used to accelerate distribution and reduce supply risk. Investor scrutiny around R&D productivity has prompted tighter prioritization of programs with clear clinical differentiation or regulatory incentives. Overall, corporate strategies are converging on a balanced mix of innovation, cost discipline, and partnership to sustain competitiveness while addressing payer and patient expectations.

Practical and high-leverage recommendations for executives to strengthen supply resilience, evidence generation, and value-driven commercialization in OCD therapeutics

Industry leaders seeking to strengthen their position in the OCD therapeutic domain should prioritize a set of pragmatic, high-impact actions that enhance resilience and commercial differentiation. First, align clinical development choices with payer evidence requirements by integrating health economics and outcomes research early in trial design to shorten the path to formulary acceptance. Simultaneously, fortify supply chains through regional diversification and strategic manufacturing agreements to reduce exposure to trade policy shocks and ensure continuity of supply.

Leaders should also invest in digital and patient-support services that improve adherence and real-world outcomes, thereby reinforcing product value propositions. Partnerships with behavioral health providers and telemedicine platforms can extend reach into under-served patient segments and create integrated care solutions. Finally, adopt dynamic pricing and contracting frameworks that reflect value delivered across varied care settings, and maintain an active watch on regulatory and reimbursement shifts to respond nimbly. Executing these coordinated moves will better position companies to deliver clinically meaningful innovations while safeguarding access and commercial viability.

Transparent, multi-method research approach integrating primary stakeholder interviews with systematic secondary evidence to deliver reliable, reproducible strategic insights

The research underpinning this executive analysis combines primary and secondary approaches to ensure robust, triangulated insights. Primary engagement included structured interviews with clinicians, payers, procurement officers, and manufacturing experts to capture operational realities, prescribing behavior, and access constraints across care settings. Secondary research entailed systematic reviews of peer-reviewed clinical literature, regulatory guidance documents, clinical trial registries, and publicly available safety reports to validate therapeutic trends and evidence gaps.

Analytical techniques integrated qualitative synthesis with quantitative trend analysis where appropriate, including time-series examination of regulatory filings, patent landscapes, and supply chain event histories. Cross-validation was achieved through subject matter expert consultations and scenario-based sensitivity checks to test assumptions about supply risk and policy impact. Ethical considerations and data provenance were maintained throughout the process, with a clear emphasis on transparency and reproducibility of methods to support confident decision-making by stakeholders.

Executive synthesis emphasizing the imperative to integrate clinical differentiation, supply resilience, and patient-centric strategies to achieve sustainable impact in OCD therapeutics

In conclusion, the contemporary OCD therapeutic environment is characterized by simultaneous pressures and opportunities across clinical, regulatory, and commercial dimensions. Advances in clinical understanding and the emergence of complementary digital interventions are opening pathways for improved patient outcomes, while trade policy shifts and intensified generic competition are reshaping cost and supply dynamics. Decision-makers must therefore integrate evidence generation, supply chain resilience, and patient-centric support services into cohesive strategies that reflect regional market realities and payer expectations.

By prioritizing differentiated clinical value, strengthening manufacturing and sourcing flexibility, and leveraging partnerships to extend care delivery, stakeholders can navigate policy volatility and competitive pressure while improving access for patients. The combined effect of these actions will determine which organizations can sustainably translate scientific progress into broad clinical impact and enduring commercial success.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Obsessive-Compulsive Disorder Drugs Market, by Drug Class

  • 8.1. MAOIs
    • 8.1.1. Phenelzine
    • 8.1.2. Tranylcypromine
  • 8.2. SNRIs
    • 8.2.1. Desvenlafaxine
    • 8.2.2. Duloxetine
    • 8.2.3. Venlafaxine
  • 8.3. SSRIs
    • 8.3.1. Citalopram
    • 8.3.2. Fluoxetine
    • 8.3.3. Fluvoxamine
    • 8.3.4. Paroxetine
    • 8.3.5. Sertraline
  • 8.4. TCAs
    • 8.4.1. Amitriptyline
    • 8.4.2. Clomipramine
    • 8.4.3. Imipramine

9. Obsessive-Compulsive Disorder Drugs Market, by Distribution Channel

  • 9.1. Hospital Pharmacy
  • 9.2. Online Pharmacy
  • 9.3. Retail Pharmacy

10. Obsessive-Compulsive Disorder Drugs Market, by Drug Type

  • 10.1. Brand
  • 10.2. Generic

11. Obsessive-Compulsive Disorder Drugs Market, by Route Of Administration

  • 11.1. Oral
  • 11.2. Parenteral

12. Obsessive-Compulsive Disorder Drugs Market, by End User

  • 12.1. Clinics
  • 12.2. Hospitals
  • 12.3. Households

13. Obsessive-Compulsive Disorder Drugs Market, by Patient Age Group

  • 13.1. Adult
  • 13.2. Pediatric

14. Obsessive-Compulsive Disorder Drugs Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Obsessive-Compulsive Disorder Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Obsessive-Compulsive Disorder Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Obsessive-Compulsive Disorder Drugs Market

18. China Obsessive-Compulsive Disorder Drugs Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc
  • 19.6. Alembic Pharmaceuticals Ltd
  • 19.7. Amneal Pharmaceuticals Inc
  • 19.8. Apotex Inc
  • 19.9. AstraZeneca PLC
  • 19.10. Aurobindo Pharma Limited
  • 19.11. Biogen Inc
  • 19.12. Dr Reddy's Laboratories Ltd
  • 19.13. Eli Lilly and Company
  • 19.14. GlaxoSmithKline plc
  • 19.15. H Lundbeck A/S
  • 19.16. Johnson & Johnson
  • 19.17. Lupin Pharmaceuticals Inc
  • 19.18. Mallinckrodt plc
  • 19.19. Merck & Co Inc
  • 19.20. Novartis AG
  • 19.21. Omeros Corporation
  • 19.22. Otsuka Pharmaceutical Co Ltd
  • 19.23. Pfizer Inc
  • 19.24. Sanofi
  • 19.25. Sun Pharmaceutical Industries Ltd
  • 19.26. Teva Pharmaceutical Industries Ltd
  • 19.27. Torrent Pharmaceuticals Ltd
  • 19.28. Viatris Inc
  • 19.29. Zydus Pharmaceuticals Inc

LIST OF FIGURES

  • FIGURE 1. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PHENELZINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PHENELZINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PHENELZINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TRANYLCYPROMINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TRANYLCYPROMINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TRANYLCYPROMINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DESVENLAFAXINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DESVENLAFAXINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DESVENLAFAXINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DULOXETINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DULOXETINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DULOXETINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY VENLAFAXINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY VENLAFAXINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY VENLAFAXINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CITALOPRAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CITALOPRAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CITALOPRAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY FLUOXETINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY FLUOXETINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY FLUOXETINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY FLUVOXAMINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY FLUVOXAMINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY FLUVOXAMINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PAROXETINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PAROXETINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PAROXETINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SERTRALINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SERTRALINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SERTRALINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY AMITRIPTYLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY AMITRIPTYLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY AMITRIPTYLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CLOMIPRAMINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CLOMIPRAMINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CLOMIPRAMINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY IMIPRAMINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY IMIPRAMINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY IMIPRAMINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY BRAND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY BRAND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY BRAND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOUSEHOLDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOUSEHOLDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOUSEHOLDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 200. GCC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. GCC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 202. GCC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 203. GCC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 204. GCC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 205. GCC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 206. GCC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. GCC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. GCC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 209. GCC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. GCC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 233. G7 OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. G7 OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 235. G7 OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 236. G7 OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 237. G7 OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 238. G7 OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 239. G7 OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 240. G7 OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. G7 OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 242. G7 OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. G7 OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 244. NATO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. NATO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 246. NATO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 247. NATO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 248. NATO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 249. NATO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 250. NATO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 251. NATO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. NATO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 253. NATO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. NATO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 255. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 269. CHINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 272. CHINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)